

**BLOOD BANKING/TRANSFUSION MEDICINE
CONTENT SPECIFICATIONS 2011**

New Validated Practical Knowledge

Pre-Transfusion

1. Donor Recruitment, Selection, Complications
 - a. automated multiple component donation, including risks, benefits, and regulations (double RBCs, double-triple platelets, combinations of multiple components)
2. Testing of Donor Units
 - a. use of multiplex PCR for NAT (West Nile Virus, Hep B, Hep C)
 - b. Chagas disease testing
 - c. bacterial contamination of platelets
 - d. donor selection and anti-leukocyte antibody testing for TRALI
 - e. parvovirus B19 (plasma derivatives)
3. Preparation, Storage, and Release of Blood Components and Derivatives
 - a. pathogen inactivation (including general methods, strengths and weaknesses)
4. Compatibility Testing of Red Cells and Components
 - a. molecular immunohematology, including general methods, strengths, and weaknesses

References

- Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis, platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). *Transfusion* 2007; 45:1413-25.
- Vamvakas, EC and Blajchman, MA. Critical review of universal leukocyte-reduction. *Transfusion* 2001; 41: 691-712.
- McCullough J et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation. The SPRINT Trial. *Blood* 2004; 104:1534-41.
- Aubuchon JP et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. *Transfusion* 2005; 45:1335-41
- Webert KE, et al. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. *Transfusion Med Rev* 2008; 22:134.
- Poole J, Daniels G. Blood group antibodies and their significance in transfusion medicine. *Transfusion Medicine Reviews* 2007; 21:58-71.
- Reid ME. Applications of DNA-based assays in blood group antigen and antibody identification. *Transfusion* 2003 (Dec); 43:1748-57.
- Denomme GA, Van Oene M. High throughput multiplex single nucleotide polymorphism analysis for red cell and platelet antigen genotypes. *Transfusion* 2005; 45:660-66
- Beiboer SHW et al. Rapid genotyping of blood group antigens by multiplex polymerase chain reaction and DNA microarray hybridization. *Transfusion*:45:667-79.
- Hashmi G, et al . A flexible array format for large scale, rapid blood group DNA typing. *Transfusion* 2005; 45:680-8.
- Hillyer C, Shaz B, Reid M. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. *Transfus Med Rev* 2008; 22:117-32.

Transfusion Practices

1. Indications for Use of Components and Derivatives
 - a. platelet transfusion trigger - physiology and goals of treatment
 - b. considerations for neutrophil/granulocyte transfusions from G-CSF and/or corticosteroid stimulated donors
 - c. use/indications for FP24 and thawed plasma
 - d. fresh vs stored RBC transfusions
2. Special Transfusion Situations
 - a. sickle cell disease
simple RBD transfusions vs exchange transfusion or erythrocytapheresis
alloimmunization
hyperhemolysis
 - b. transfusion of known incompatible blood
 - c. transfusing patients with autoimmune hemolytic anemia
 - d. massive transfusion
roles/timing of plasma, platelets, RBCs and non-blood fluids
 - e. guidelines for red blood cell transfusion to critically-ill patients
 - f. advances in prenatal evaluation and management of hemolytic disease of the fetus/newborn
 - g. neonatal/pediatric transfusions
3. Blood conservation by combined methodologies
 - a. pharmacologic
 - b. transfusion guidelines
 - c. coagulopathy diagnosis
 - d. autologous reinfusion
 - e. anesthesia techniques
4. Special Transfusion Considerations in Transplant Patients
 - a. effect of graft lymphocyte content on outcomes in autologous transplantation
 - b. use of C4 and fixation, Luminex-based HLA antibody testing for predicting solid organ graft rejection
 - c. use of ABO incompatible donors for renal transplantation test systems
 - d. antibody reduction methods
 - e. immune monitoring post-transplant
 - f. appropriate ABO, Rh, and HLA matching requirements for transplants
bone marrow
cord blood
kidney
liver
pancreas
heart/lung
 - g. cGMP manufacturing of cellular therapies
5. Therapeutic Apheresis and Phlebotomy
 - a. critical analysis of therapeutic hemapheresis practices - awareness of technologies and when they might be used
 - b. indications for plasma exchange & considerations for IVIG as an alternative/adjunctive therapy.

References

- Buhrkuhl DC. An update on platelet transfusion in hemato-oncology supporting care. *Transfusion* 2010; 50: 2266-2276.
- Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med.* 1999; 340 (6):409-17.
- Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. *Lancet* 2007; 370:415-26.
- Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. *Brit. J. Haemat.* 2006; 133:364-374.
- Dzik WH. How I do it: Platelet support for refractory patients. *Transfusion* 2007; 47: 374-378.
- Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. *Transfusion Med. Reviews* 2004; 18: 153-167.
- Hardy JF, de Moerloose P, Samama M. et al. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. *Can J Anest* 2004; 51: 293-310.
- Josephson CD, SuLL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. *Transfus Med Rev.* 2007; 21:118-33.
- Vamvakas ED. Meta-analysis of clinical studies of the purported deleterious effects of "old" (versus "fresh") RBCs: Are we at equipoise? *Transfusion* 2010; 50: 600-610.
- Strauss RG. Data-driven blood banking practices for neonatal RBC transfusions. *Transfusion* 2000; 40:1528-40.
- Lacroix J, Hebert PC, Hutchison JS et al. Transfusion strategies for patients in pediatric intensive care units. *New Engl J Med* 2007; 356: 1609-19.
- Strauss RG. How I transfuse RBCs and platelets to infants. *Transfusion* 2008; 48: 209-217.
- Key NS, Negrier C. Coagulation factor concentrates: past, present and future. *Lancet* 2007; 370:439-48.
- Segal JB and Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. *Transfusion* 2004; 45: 1413-25.
- Dzik, WH. Blood Components to Achieve Hemostasis for Surgery and Invasive Procedures. In Simon, T et al (ed). *Rossi's Principles of Transfusion Medicine*, AABB Press, 4th ed., 2009, pp 575-588.
- Critical review of VIIa physiology and applications. *Ann Rev. Med* 2008; 59: 185-197.
- O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA* 2006; 295: 293-8.
- Wong CJ, Vandervoort SL, Vandervoort A et al. A cluster-randomized controlled trial of blood conservation algorithm in patients undergoing total hip joint arthroplasty. *Transfusion* 2007; 47:832-841.
- Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines of the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. *J. Clin Apher.* 2010; 25: 96-188.
- Copelan EA. Hematopoietic stem-cell transplantation. *N. Engl. J. Med.* 2006; 354: 1813-26.
- Susal C, Opelz G. Options for immunological support for renal transplantation through the HLA and Immunology laboratory. *Am J. Transplant* 2007; 7:1450-1456.
- Strauss RG. Granulocyte (neutrophil) Transfusion Therapy. IN: Mintz PD (ed). *Transfusion Therapy: Clinical Principles and Practice* (3rd ed). Bethesda, AABB Press, 2011:433-448.

Complications of Transfusion

1. Diagnosis and Management of Non-Infectious Complications
2. Transfusion Associated Acute Lung Injury (TRALI)
diagnosis
evaluation
approaches to therapy
risk reduction
3. Transfusion Associated Circulatory Overload (TACO)
4. Inflammatory responses to transfusion resulting in poor outcome
5. Transfusion-Transmitted Infectious Disease
Rates and methods of reduction for emerging infections

References

- Kleinman S, Caulfield T, Chan P et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion* 2004; 44: 1774-89.
- Goldman M., Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of TRALI. *Transfusion Med Rev* 2005; 19: 2-31.
- Bux J and Sachs UJH. The pathogenesis of transfusion-related acute lung injury (TRALI) *Brit J Haematol* 2007; 136:788-99.
- Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. *Transfusion* 2010; 50: 2080-2099.
- Emerging infectious disease agents and their potential threat to transfusion safety. *Transfusion* 2009; 49: supplement 2S, August.

Tissue Banking

1. cGTPs and implications for the tissue portion of blood banks

Management

1. Updates to AABB Standards and FDA Regulations